CovidChloroV1, Main, Corpus, bibRecord, 000D35

Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.

Identifieur interne : 000D35 ( Main/Corpus ); précédent : 000D34; suivant : 000D36

Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.

Auteurs : Tung Hoang ; Tho Tran Thi Anh

Source :

Infection & chemotherapy [ 2093-2340 ] ; 2020.

RBID : pubmed:32869558

Abstract

Coronaviruses have caused serious Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19) outbreaks, and only remdesivir has been recently indicated for the treatment of COVID-19. In the line of therapeutic options for SARS and MERS, this study aims to summarize the current clinical evidence of treatment options for COVID-19. In general, the combination of antibiotics, ribavirin, and corticosteroids was considered as a standard treatment for patients with SARS. The addition of this conventional treatment with lopinavir/ritonavir, interferon, and convalescent plasma showed potential clinical improvement. For patients with MERS, ribavirin, lopinavir/ritonavir, interferon, and convalescent plasma were continuously recommended. However, a high-dose of corticosteroid was suggested for severe cases only. The use of lopinavir/ritonavir and convalescent plasma was commonly reported. There was limited evidence for the effect of corticosteroids, other antiviral drugs like ribavirin, and favipiravir. Monoclonal antibody of tocilizumab and antimalarial agents of chloroquine and hydroxychloroquine were also introduced. Among antibiotics for infection therapy, azithromycin was suggested. In conclusion, this study showed the up-to-date evidence of treatment options for COVID-19 that is helpful for the therapy selection and the development of further guidelines and recommendations. Updates of on-going clinical trials and observational studies may confirm the current findings.

DOI: 10.3947/ic.2020.52.3.317
PubMed: 32869558
PubMed Central: PMC7533202

Links to Exploration step

pubmed:32869558

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.</title>
<author><name sortKey="Hoang, Tung" sort="Hoang, Tung" uniqKey="Hoang T" first="Tung" last="Hoang">Tung Hoang</name>
<affiliation><nlm:affiliation>Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Anh, Tho Tran Thi" sort="Anh, Tho Tran Thi" uniqKey="Anh T" first="Tho Tran Thi" last="Anh">Tho Tran Thi Anh</name>
<affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Nghe An Oncology Hospital, Nghe An, Vietnam. trananhthohmu@gmail.com.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32869558</idno>
<idno type="pmid">32869558</idno>
<idno type="doi">10.3947/ic.2020.52.3.317</idno>
<idno type="pmc">PMC7533202</idno>
<idno type="wicri:Area/Main/Corpus">000D35</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D35</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.</title>
<author><name sortKey="Hoang, Tung" sort="Hoang, Tung" uniqKey="Hoang T" first="Tung" last="Hoang">Tung Hoang</name>
<affiliation><nlm:affiliation>Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Anh, Tho Tran Thi" sort="Anh, Tho Tran Thi" uniqKey="Anh T" first="Tho Tran Thi" last="Anh">Tho Tran Thi Anh</name>
<affiliation><nlm:affiliation>Department of Gastroenterology and Hepatology, Nghe An Oncology Hospital, Nghe An, Vietnam. trananhthohmu@gmail.com.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Infection & chemotherapy</title>
<idno type="ISSN">2093-2340</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronaviruses have caused serious Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19) outbreaks, and only remdesivir has been recently indicated for the treatment of COVID-19. In the line of therapeutic options for SARS and MERS, this study aims to summarize the current clinical evidence of treatment options for COVID-19. In general, the combination of antibiotics, ribavirin, and corticosteroids was considered as a standard treatment for patients with SARS. The addition of this conventional treatment with lopinavir/ritonavir, interferon, and convalescent plasma showed potential clinical improvement. For patients with MERS, ribavirin, lopinavir/ritonavir, interferon, and convalescent plasma were continuously recommended. However, a high-dose of corticosteroid was suggested for severe cases only. The use of lopinavir/ritonavir and convalescent plasma was commonly reported. There was limited evidence for the effect of corticosteroids, other antiviral drugs like ribavirin, and favipiravir. Monoclonal antibody of tocilizumab and antimalarial agents of chloroquine and hydroxychloroquine were also introduced. Among antibiotics for infection therapy, azithromycin was suggested. In conclusion, this study showed the up-to-date evidence of treatment options for COVID-19 that is helpful for the therapy selection and the development of further guidelines and recommendations. Updates of on-going clinical trials and observational studies may confirm the current findings.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32869558</PMID>
<DateRevised><Year>2020</Year>
<Month>10</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-2340</ISSN>
<JournalIssue CitedMedium="Print"><Volume>52</Volume>
<Issue>3</Issue>
<PubDate><Year>2020</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Infection & chemotherapy</Title>
<ISOAbbreviation>Infect Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.</ArticleTitle>
<Pagination><MedlinePgn>317-334</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3947/ic.2020.52.3.317</ELocationID>
<Abstract><AbstractText>Coronaviruses have caused serious Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19) outbreaks, and only remdesivir has been recently indicated for the treatment of COVID-19. In the line of therapeutic options for SARS and MERS, this study aims to summarize the current clinical evidence of treatment options for COVID-19. In general, the combination of antibiotics, ribavirin, and corticosteroids was considered as a standard treatment for patients with SARS. The addition of this conventional treatment with lopinavir/ritonavir, interferon, and convalescent plasma showed potential clinical improvement. For patients with MERS, ribavirin, lopinavir/ritonavir, interferon, and convalescent plasma were continuously recommended. However, a high-dose of corticosteroid was suggested for severe cases only. The use of lopinavir/ritonavir and convalescent plasma was commonly reported. There was limited evidence for the effect of corticosteroids, other antiviral drugs like ribavirin, and favipiravir. Monoclonal antibody of tocilizumab and antimalarial agents of chloroquine and hydroxychloroquine were also introduced. Among antibiotics for infection therapy, azithromycin was suggested. In conclusion, this study showed the up-to-date evidence of treatment options for COVID-19 that is helpful for the therapy selection and the development of further guidelines and recommendations. Updates of on-going clinical trials and observational studies may confirm the current findings.</AbstractText>
<CopyrightInformation>Copyright © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoang</LastName>
<ForeName>Tung</ForeName>
<Initials>T</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-6653-3406</Identifier>
<AffiliationInfo><Affiliation>Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anh</LastName>
<ForeName>Tho Tran Thi</ForeName>
<Initials>TTT</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-4712-257X</Identifier>
<AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Nghe An Oncology Hospital, Nghe An, Vietnam. trananhthohmu@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Korea (South)</Country>
<MedlineTA>Infect Chemother</MedlineTA>
<NlmUniqueID>101531537</NlmUniqueID>
<ISSNLinking>1598-8112</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Evidence-based medicine</Keyword>
<Keyword MajorTopicYN="N">MERS</Keyword>
<Keyword MajorTopicYN="N">SARS</Keyword>
<Keyword MajorTopicYN="N">Treatment</Keyword>
</KeywordList>
<CoiStatement>No conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32869558</ArticleId>
<ArticleId IdType="doi">10.3947/ic.2020.52.3.317</ArticleId>
<ArticleId IdType="pii">52.e59</ArticleId>
<ArticleId IdType="pmc">PMC7533202</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Intern Med. 2004 Apr;255(4):512-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15049886</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine Growth Factor Rev. 2014 Aug;25(4):369-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25156421</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Oct;63(10):1515-1521</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32418114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Mar 13;367(6483):1260-1263</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Jul;583(7815):286-289</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32380510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2018 Jul;44(7):1003-1016</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29761216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 May;46(5):854-887</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Chim Acta. 2020 Oct;509:280-287</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32531256</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Chemother. 2020 Jun;52(2):281-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32342676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 May;59(5):414-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15115870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2018 May 2;18(1):574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29716568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 2020 Jul;75(7):1742-1752</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32239761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med (N Y). 2020 May 19;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838353</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Jun;26(6):861-868</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32327757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32284951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trop Med Int Health. 2004 Aug;9(8):923-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15303999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jul;92(7):776-785</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32297988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):e21-e23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 29;395(10225):683-684</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32122468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respirology. 2003 Nov;8 Suppl:S25-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15018130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1064-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14519241</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):e1-e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171872</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 May 03;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32361738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2016 Mar;22(3):526-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26890291</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1067-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32936266</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 May 1;248:117477</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32119961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chin Med Assoc. 2005 Jan;68(1):4-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15742856</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Chemother. 2015 Sep;47(3):212-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26483999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 May;92(5):476-478</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32056235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2017 Dec 13;12:CD007720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29236286</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2004 Jul;10(7):676-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15214887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Oct 1;290(13):1695-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14519691</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2013 Oct;17(10):e792-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23993766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2018 Jan 18;66(3):346-354</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29020323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Apr 13;35(14):e149</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32281317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Apr 15;70(9):1837-1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31925415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 May;92(5):461-463</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32073161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Tuberc Lung Dis. 2004 Oct;8(10):1173-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15527148</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Intern Med. 2020 Jul;288(1):128-138</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Engineering (Beijing). 2020 Mar 18;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32346491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2011 Mar;162(6):1239-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21091654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2013 May 27;17(3):R97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23710641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32064853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 21;323(15):1488-1494</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2020 Mar 27;12(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32230900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2015 Jul;70(7):2129-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2020 Jul 16;56(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32430428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1851-1852</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO Mol Med. 2020 Jul 7;12(7):e12421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32428990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiology. 2015 Sep;26(5):666-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26133021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32450109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2016 Dec 21;7:630</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28066439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1561-1562</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219429</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2009 May;9(5):291-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19393959</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D35 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D35 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32869558
   |texte=   Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32869558" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.

Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki